Last reviewed · How we verify

NCT07237217

Guided Group Telehealth to Deliver Evidence-based Therapeutic Care to Black College Students

Completed NA Results posted Last updated 23 February 2026
What this trial tests

NA trial testing Cognitive Behavioral Therapy (CBT) Coping Skills Training in Anxiety Depression in 40 participants. Completed in 31 August 2025.

Timeline
22 September 2024
Primary endpoint
31 August 2025
31 August 2025

Quick facts

Lead sponsorDr. Veronica Tetterton
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment40
Start date22 September 2024
Primary completion31 August 2025
Estimated completion31 August 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Dr. Veronica Tetterton

Who can join

18 and older, any sex, with Anxiety Depression. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Completion Rate Secondary · 12 weeks

Out of the 20 participants in each clinical trial arm, this outcome reflects the number of participants who completed the engagement component by Week 12 of the intervention.

GroupValue95% CI
Guided Group Therapy (GGT) Via TheraGroup15
Individual Teletherapy (IT)17
Engagement (8-item Scale) Primary · Week 4

Participant engagement was assessed using a self-report engagement measure administered at post-intervention. Items were rated on a 5-point Likert-type scale ranging from 1 to 5, with higher scores indicating greater engagement. Mean engagement scores are reported as scores on a scale. Engagement scores represent the mean of all item responses, yielding a possible score range from 1 to 5.

GroupValue95% CI
Guided Group Therapy (GGT) Via TheraGroup3.90± .12
Individual Teletherapy (IT)4.62± .12
Engagement (8-item Scale) Primary · Week 8

Participant engagement was assessed using a self-report engagement measure administered at post-intervention. Items were rated on a 5-point Likert-type scale ranging from 1 to 5, with higher scores indicating greater engagement. Mean engagement scores are reported as scores on a scale. Engagement scores represent the mean of all item responses, yielding a possible score range from 1 to 5.

GroupValue95% CI
Guided Group Therapy (GGT) Via TheraGroup4.11± .12
Individual Teletherapy (IT)4.70± .12
Engagement (8-item Scale) Primary · Week 12

Participant engagement was assessed using a self-report engagement measure administered at post-intervention. Items were rated on a 5-point Likert-type scale ranging from 1 to 5, with higher scores indicating greater engagement. Mean engagement scores are reported as scores on a scale. Engagement scores represent the mean of all item responses, yielding a possible score range from 1 to 5.

GroupValue95% CI
Guided Group Therapy (GGT) Via TheraGroup3.74± .12
Individual Teletherapy (IT)4.79± .12
Anxiety Symptoms (GAD-7) Primary · Week 12

Anxiety symptoms were assessed using the Generalized Anxiety Disorder 7-item scale (GAD-7). Items are rated on a 4-point scale ranging from 0 ("not at all") to 3 ("nearly every day"). Item responses are summed to compute a total score. Total scores range from 0 to 21, with higher scores indicating greater anxiety symptom severity.

GroupValue95% CI
Guided Group Therapy (GGT) Via TheraGroup14.91± 1.12
Individual Teletherapy (IT)11.69± 1.19
Anxiety Symptoms (GAD-7) Primary · Week 8

Anxiety symptoms were assessed using the Generalized Anxiety Disorder 7-item scale (GAD-7). Items are rated on a 4-point scale ranging from 0 ("not at all") to 3 ("nearly every day"). Item responses are summed to compute a total score. Total scores range from 0 to 21, with higher scores indicating greater anxiety symptom severity.

GroupValue95% CI
Guided Group Therapy (GGT) Via TheraGroup13.79± 1.12
Individual Teletherapy (IT)13.23± 1.19
User Feedback Sentiment Secondary · Week 4

Sentiment was quantified using a continuous sentiment score ranging from 0 to 1, with higher values indicating more positive sentiment. Sentiment scores were derived from open-ended responses collected at Week 4. Due to non-normal distributions, sentiment scores are summarized using medians and interquartile ranges and are reported as scores on a scale.

GroupValue95% CI
Guided Group Therapy (GGT) Via TheraGroup0.1340.044 – 0.170
Individual Teletherapy (IT)0.2170.100 – 0.365
User Feedback Sentiment Secondary · Week 8

Sentiment was quantified using a continuous sentiment score ranging from 0 to 1, with higher values indicating more positive sentiment. Sentiment scores were derived from open-ended responses collected at Week 8. Due to non-normal distributions, sentiment scores are summarized using medians and interquartile ranges and are reported as scores on a scale.

GroupValue95% CI
Guided Group Therapy (GGT) Via TheraGroup0.380.18 – 0.56
Individual Teletherapy (IT)0.450.26 – 0.63
User Feedback Sentiment Secondary · Week 12

Sentiment was quantified using a continuous sentiment score ranging from 0 to 1, with higher values indicating more positive sentiment. Sentiment scores were derived from open-ended responses collected at Week 12. Due to non-normal distributions, sentiment scores are summarized using medians and interquartile ranges and are reported as scores on a scale.

GroupValue95% CI
Guided Group Therapy (GGT) Via TheraGroup0.390.281 – 0.476
Individual Teletherapy (IT)0.3930.255 – 0.476
Anxiety Symptoms (GAD-7) Primary · Week 4

Anxiety symptoms were assessed using the Generalized Anxiety Disorder 7-item scale (GAD-7). Items are rated on a 4-point scale ranging from 0 ("not at all") to 3 ("nearly every day"). Item responses are summed to compute a total score. Total scores range from 0 to 21, with higher scores indicating greater anxiety symptom severity.

GroupValue95% CI
Guided Group Therapy (GGT) Via TheraGroup13.09± 1.19
Individual Teletherapy (IT)13.02± 1.19
Anxiety Symptoms (GAD-7) Primary · Baseline

Anxiety symptoms were assessed using the Generalized Anxiety Disorder 7-item scale (GAD-7). Items are rated on a 4-point scale ranging from 0 ("not at all") to 3 ("nearly every day"). Item responses are summed to compute a total score. Total scores range from 0 to 21, with higher scores indicating greater anxiety symptom severity.

GroupValue95% CI
Guided Group Therapy (GGT) Via TheraGroup10.01± 0.98
Individual Teletherapy (IT)8.96± 1.05
Depressive Symptoms (PHQ-9) Primary · Baseline

Depressive symptoms were assessed using the Patient Health Questionnaire-9 (PHQ-9), a 9-item self-report measure. Items are rated on a 4-point scale ranging from 0 ("not at all") to 3 ("nearly every day"). Item responses are summed to compute a total score. Total scores range from 0 to 27, with higher scores indicating greater depressive symptom severity.

GroupValue95% CI
Guided Group Therapy (GGT) Via TheraGroup10.62± 0.99
Individual Teletherapy (IT)9.90± 1.08

Sponsor's own description

The goal of this study is to address the mental health crisis among college students by creating a promising solution for group teletherapy, which is equivalent to individual teletherapy in terms of treatment outcomes.The main question it aims to answer is: if participants' outcome measures in TheraGroup are in line with participants' outcome measures in individual therapy. The goal of the current SBIR is to test TheraGroup, the first large scale virtual group platform for evidenced-based mental health therapy. The TheraGroup application addresses the market surge in the demand for care and the shortage of mental health professionals as it represents an economically viable treatment alternative to individual teletherapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Anxiety Depression

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07237217.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing